Regeneron Pharmaceuticals said an independent panel found the company’s Covid-19 antibody cocktail to have “clear clinical efficacy” in reducing the rates of hospitalization and deaths in patients.
Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab-rwlc) won U.S. Food and Drug Administration approval for the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression.
In a long-running court battle over PCSK9 antibodies, Amgen lost the company’s bid to uphold patent claims for the cholesterol drug Repatha against rival drug Praluent, developed by Sanofi and Regeneron.
Laboratory testing found that Regeneron Pharmaceuticals Inc.’s Covid-19 antibody cocktail can combat a coronavirus variant first found in South Africa, but a similar drug from Eli Lilly and Co. is inactive against it, according to a study.
Regeneron Pharmaceuticals announced positive initial data from the company’s ongoing Phase III trial of the antibody cocktail, REGEN-COV, as a passive vaccine to prevent Covid-19 in people at high risk of infection from household exposure.
Regeneron Pharmaceuticals Inc. said initial data from an ongoing study of the company’s experimental antibody cocktail for use in hospitalized Covid-19 patients requiring low-flow oxygen show the therapy was sufficiently effective to warrant continuing the trial.
Swiss drugmaker Roche’s experimental eye medicine faricimab matched Bayer and Regeneron’s Eylea against diabetic macular degeneration in acuity gains in two studies, including one in which patients had less-frequent shots.
U.S. hospitals have been slow to embrace Covid-19 antibody drugs from Eli Lilly and Co. and Regeneron Pharmaceuticals Inc. that were authorized to reduce the risk of hospitalization, U.S. officials said.
Regeneron Pharmaceuticals Inc. paused patient enrollment in two clinical studies testing the company’s experimental lymphoma drug, after the U.S. health regulator requested changes in trial protocols.
Sanofi and Regeneron’s Dupixent product won approval from the European Commission to treat children aged 6-11 years suffering from severe atopic dermatitis, often known as eczema.